Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06619561 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Evaluate Vimseltinib in Adults With Active Chronic Graft-Versus-Host Disease (cGVHD)

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Study sites: 25 to 26v25
  2. Study sites: 24 to 25v24
  3. Study sites: 23 to 24v23
  4. Eligibility criteria expanded, about 1 wordv22
  5. Enrollment target: 36 to 48
    • Study sites: 22 to 23
    • Eligibility criteria expanded, about 11 words
    • Secondary endpoints: details revised at 2 of 5 entries
    v21
Show 19 earlier versionsHide 19 earlier versions
  1. Study sites: 21 to 22v20
  2. Study sites: 20 to 21v19
  3. Study sites: 19 to 20v18
  4. Study sites: 18 to 19v17
  5. Study sites: 17 to 18v16
  6. Study sites: 16 to 17v15
  7. Study sites: 15 to 16v14
  8. Study sites: 14 to 15v13
  9. Study sites: 13 to 14v12
  10. Study sites: 12 to 13v11
  11. Study sites: 11 to 12v10
  12. Study sites: 10 to 11v9
  13. Study sites: 6 to 10v8
  14. Study sites: 5 to 6v7
  15. Study sites: 4 to 5v6
  16. Study sites: 3 to 4v5
  17. Study sites: 2 to 3v4
  18. Study sites: 1 to 2
    • Start date changed from estimate of Dec 2024 to Nov 21, 2024
    v3
  19. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Study title shortened, about 2 words
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to determine if vimseltinib is safe, tolerable and works effectively to treat adults with active moderate to severe cGVHD. Participants will be treated with vimseltinib in 28-day treatment cycles for approximately 2 years.
Trial Details
NCT Number NCT06619561
Lead Sponsor Deciphera Pharmaceuticals, LLC
Conditions
(from sponsor)		 Chronic Graft-Versus-Host Disease (cGVHD)
Related terms Bronchial Diseases, Bronchiolitis, Bronchiolitis Obliterans, Bronchiolitis Obliterans Syndrome, Fibrosis, Graft vs Host Disease, Immune System Diseases, Liver Diseases, Lung Diseases, Lung Diseases, Obstructive, Organizing Pneumonia, Respiratory Tract Diseases, Sclerosis
Enrollment 48 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov